CRISPR Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 10.18 M
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 10.18 M, beating the estimate of USD 7.43 M.
EPS: As of FY2026 Q2, the actual value is USD -0.94, beating the estimate of USD -1.1714.
EBIT: As of FY2026 Q2, the actual value is USD -90.19 M.
The provided reference, a Form 8-K filed by CRISPR Therapeutics AG, announces the release of its financial results for the quarter ended June 30, 2026, and other business highlights on August 3, 2026. However, the document explicitly states that actual financial and operational metrics, as well as any outlook or guidance, are not included within this document . Therefore, no specific financial metrics, operational metrics, or outlook information can be extracted from the provided text.